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Abstract
Background: Altered levels of Immunoglobulin E (IgE) represent a dysregulation of IgE synthesis and may be seen
in a variety of immunological disorders. The object of this review is to summarize the historical and molecular
aspects of IgE synthesis and the disorders associated with dysregulation of IgE production.
Methods: Articles published in Medline/PubMed were searched with the keyword Immunoglobulin E and specific
terms such as class switch recombination, deficiency and/or specific disease conditions (atopy, neoplasia, renal
disease, myeloma, etc.). The selected papers included reviews, case reports, retrospective reviews and molecular
mechanisms. Studies involving both sexes and all ages were included in the analysis.
Results: Both very low and elevated levels of IgE may be seen in clinical practice. Major advancements have been
made in our understanding of the molecular basis of IgE class switching including roles for T cells, cytokines and T
regulatory (or Treg) cells in this process. Dysregulation of this process may result in either elevated IgE levels or IgE
deficiency.
Conclusion: Evaluation of a patient with elevated IgE must involve a detailed differential diagnosis and
consideration of various immunological and non-immunological disorders. The use of appropriate tests will allow
the correct diagnosis to be made. This can often assist in the development of tailored treatments.
Introduction
Immunoglobulin E has traditionally been associated with
atopic disease and systemic anaphylaxis. However, its
role in host defense, parasitic infection and immune sur-
veillance suggest many other potential functions. The
initial description of anaphylaxis was made by Portier
and Richet in 1902 which led to Richet receiving the
Nobel Prize for medicine in 1913 (Figure 1A). The mast
cell was first described by Paul Ehrlich while experi-
menting with Aniline dyes as a medical student in 1878
(Figure 1B and 1C); he was awarded the Nobel Prize for
his therapeutic discoveries in Medicine in 1908. The dis-
covery of IgE by the Ishizakas (Figure 1D) in 1966 was a
major advancement. Further understanding of IgE
immunobiology was made possible by the description of
class switch recombination (discussed later) by Susumu
Tonegawa (Figure 1E), a Japanese scientist working in
the United States. For this, he was awarded the Nobel
Prize in Medicine in 1985.
Molecular Regulation of IGE Production
Immunoglobulin E is a class of immunoglobulin essential
for the allergic response (Figure 1F). IgE is formed by the
B lymphocyte and after several gene rearrangement steps
is secreted. The production of IgE is regulated by genes,
cytokines and the environment (Figure 2).
Immunoglobulin E consists of two identical heavy
chains and two identical light chains with variable (V)
and constant (C) regions (Figure 1F). The ε-heavy chains
contain one variable heavy chain and four constant
region domains (Cε 1-4). Immunoglobulin domains each
contain around 110 amino acids and are beta sheets
with three and four beta strands in the C type topology
[1]. IgE is a component of a network of proteins
involved in the signaling response to an allergen/anti-
gen. These proteins include FcεRI, the high affinity
receptor for IgE, CD23 (also known as FcεRII), the low
affinity receptor for IgE, and galactin-3, the IgE and
FcεRI binding protein. The known physiological proper-
ties of IgE are summarized in Table 1. Binding of IgE to
FcεRI on mast cells and basophils induces signaling and
leads to mast cell degranulation and mediator release.
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of cytokines, chemokines and growth factors. These
mediators are partially responsible for eosinophil activa-
tion and survival seen in many disorders associated with
elevated IgE [2-6].
Cell-Cell Interactions in IgE Synthesis
In the accepted model, an antigen/allergen is presented
by a B cell, in the context of MHC class II molecules, to
a Th2 cell, which recognizes the antigen via its T cell
receptor (TcR)/CD3 complex. This leads to the expres-
sion of CD154 (or CD40 ligand) on the T cell, which
engages the counter-receptor, CD40, to be expressed on
B cells. This engagement of TcR/CD3, MHC II, antigen/
peptide, CD154 and CD40 at the “immune synapse”
leads to a sequence of events culminating in IgE secre-
tion by the B cell (Figure 3). The sequential events
include induction of CD 80/86 on the B cell that
engages CD28 on the T cell, leading to transcription of
pivotal Th2 cytokines IL-4 and/or IL-13. Following
secretion, these cytokines bind to corresponding recep-
tors (IL-13R or IL-4R) on the B cell, leading to STAT6
activation in B cells. This synergizes with Nf-B, acti-
vated via switch receptors (CD40 and others), to induce
activation-induced cytosine deaminase (AID) which
induces class switch recombination (Figure 3) and acti-
vates germline transcription of Cε.
IgE Class-Switch Recombination
A two-step process of DNA excision and ligation are
required for assembly of a functional IgE. In the primary
response, characterized by expression of membrane IgM
and IgD, VDJ (heavy chain) and VJ (light chain) recom-
bination occurs in fetal tissue (liver and bone marrow).
Figure 1 Historical aspects of Immunoglobulin E. Charles Richet (A-Credit: Wellcome Library, London: Charles Robert Richet), Paul Ehrlich (B
and C-Wellcome Library, London Portrait of P. Ehrlich at work in his laboratory), Teruko and Kimishige Ishizaka (D- Courtesy of the Alan Mason
Chesney Medical Archives, Johns Hopkins Medical Institutions), Susumu Tonegawa (E- Courtesy Dr. Susumu Tonegawa) and IgE molecule
structure (F).
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cess. In the secondary immune response, which results
in formation of the isotypes IgG, IgA and IgE, class
switch recombination (CSR) occurs in secondary lym-
phoid tissues (lymphoid tissue, spleen and tonsils). This
is T cell/cytokine dependent and an antigen dependent
process. This results in high affinity antibodies, further
modified by the process of somatic hypermutation
(SHM). SHM results from missense mutations in the V
regions of the immunoglobulin molecule.
First, during the pre-B cell stage, the individual heavy
chain variable (VH), diversity (D) and joining (JH)e x o n s
randomly combined to form a VH(D)JH cassette that
encodes an antigen-specific VH domain. This cassette is
upstream of the constant μ exons and allows for the
assembly of complete VDJ exons that encode an anti-
gen-binding VH domain which produces intact μ heavy
chains. The second step, class-switch recombination, is
required for mature B cells to alter the isotope of their
antibodies, while retaining their antigen specificity. This
involves tightly regulated and irreversible exchange of
the various isotope’s VHJ cassette to construct different
heavy chains [7]. The Cε locus of IgE is similar to other
CH loci. The 5’ region of each heavy chain isotope gene
includes switch regions with tandem repeats, known as
Sε and μ. In CSR, two switch regions, Sε and μ are com-
bined, which allows the joining of the VH(D)JH and Cε
regions. This joining generates a functional gene
Figure 2 Factors regulating IgE production.
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by cytokines IL-4 or IL-13 secreted by T helper 2 (TH2)
cells [8].
The Role of T cells, Cytokines and Tregs
Several T cell derived cytokines play a pivotal role in IgE
CSR and expression (Figure 4). The cytokines that induce
IgE CSR and/or IgE production in humans include: IL-4
and IL-13 (essential for CSR), TSLP (increases IL-4 and
IL-13), IL-18 (increases IL-4 and IL-13 in some systems),
IL-25 (increases IL-4 and IL-13) and IL-33 (increases IL-
4 and IL-13). The authors showed that polymorphisms in
chromosome 5q31.1 (Th2 cytokine cluster including IL-4
gene) were associated with IgE levels using sib-pair analy-
sis [9]. The following cytokines inhibit IgE CSR and/or
production: IFNg,I L - 1 0 ,I F Na and b (inhibit IgE pro-
duction and also inhibit Th2 cytokine generation), TGF b
and IL-21.
Figure 3 T-B cell interactions, immune synapse (Prepared for the manuscript by Rahul Krishnaswamy) and IgE class switch
recombination (shown in inset).
Table 1 The Physiological Properties of Immunoglobulin E
General Characteristics Molecular weight: 190,000 Da (170 kDa protein; 20 kDa Carbohydrate)
Type: Monomer
Subclasses: None
Biology Does not fix complement
Does not cross the placental barrier
Half-life: 2 days
Isoforms: Secreted and membrane bound IgE
Structure: Two light chains ( or l) and 2 heavy chains (ε)
Function Binds to High affinity IgE receptor (FcεRI) and degranulates mast cells and basophils
Immediate Hypersensitivity
IgE-mediated antigen presentation via FcεRI
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the regulation of IgE synthesis. In the presence of speci-
fic growth factors and cytokines, T cell precursors can
develop into Th1, Th2, Th17 and Treg cells (Figure 5).
Th2 cells, regulated by GATA3 and STAT6 transcrip-
tion factors, enhance IgE CSR (IL-4 and IL-13) and
synthesis, while Th1 cells, regulated by T-bet and
STAT4, inhibit the Th2-IgE axis. T cells with regulatory
function include traditional Treg cells, Th3 cells
(expressing TGF b) and Tr1 cells (peripherally-derived
Treg cells expressing IL-10). These cells have negative
regulatory effects on IgE synthesis. Tregs express CD25
and FOXP3 transcription factor and are thymically-
derived. They develop from CD4+ precursor cells in the
presence of retinoic acid (RA), TGF b and IL-2. By
expressing TGFb and IL-10, Tregs inhibit IgE CSR and
synthesis.
Ige Dysregulation
Normal levels of IgE are highly variable in the popula-
tion. Factors regulating IgE levels include age, gene-by-
environment interactions, genetic factors (such as cer-
tain polymorphisms), racial factors (higher levels are
seen in African Americans and persons of Filipino des-
cent), sex (males tending to have higher levels) and sea-
son (IgE levels may increase during pollen season in
allergic individuals).
Immune Dysregulation Associated with IGE
Deficiency
IgE hypogammaglobulinemia is currently defined as a
significant decrease in serum levels of IgE (<2.5 IU/mL)
in a patient whose other immunoglobulin levels are nor-
mal (selective IgE deficiency) or diminished (mixed IgE
deficiency). It is a laboratory finding that does not
necessarily equate to a clinical disorder.
The prevalence of IgE deficiency is highly dependent
on the population under study. The authors measured
serum IgE levels in 500 Red Cross (RC) blood donors,
974 allergy-immunology (AIC) patients, and 155 rheuma-
tology practice (RP) patients, and found that 2.6%, 8.1%,
and 9.7% of these subjects, respectively, had undetectable
Figure 4 Cytokine regulation of IgE production.
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donors, 3.1% of AIC patients, and 1.3% of RP patients,
and mixed in 1.8%, 5.0% and 8.4% of these cohorts,
respectively. Associated immunoglobulin deficiencies
also varied with the population under study (Table 2).
Low serum levels of IgE can also accompany other
immunologic deficiency diseases, including common
variable immunodeficiency, IgG subclass deficiencies,
ataxia telangiectasia, and Bruton’s hypogammaglobuline-
mia [10,11].
Biological Significance
Prevention and control of infection
Several early reports suggested that isolated deficiencies
in IgE predisposed to chronic sinopulmonary disease
[12,13], whereas others found no such association
[10,14]. At the time, there was no standard methodology
in use for measuring IgE levels, nor did the authors of
the reports use a common definition of what constitutes
at r u ed e f i c i e n c yi nt h i si m m u n o g l o b u l i n .H o w e v e r ,
more recent reports using standardized technologies
Figure 5 T cell subsets that have effects on IgE (Refer to text for more details).
Table 2 Prevalence of IgE Hypogammaglobulinemia
Selective deficiency Mixed deficiency Total Common associated deficiencies*
AIC patients (N = 974) 3.1% 5.0% 8.1% IgG4, IgG1, IgG2 & IgG3
RP patients (N = 155) 1.3% 8.4% 9.7% IgA2, IgA1, IgG2, IgG4
RC donors (N = 500) 0.8% 1.8% 2.6% IgG4
*In descending order of frequency
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some parasitic, bacterial, and viral infections in humans
[15-19], and possess anti-tumor properties in vitro
[20,21].
Secord and associates reported that the incidence of
opportunistic infection and failure to thrive was lower in
children with HIV-1 infection and high IgE levels than it
was in HIV-1 infected children with low or normal IgE
levels and similar decreases in CD4+ T lymphocyte
counts; IgE anti-HIV antibody was detected in 43% of the
children with high IgE levels[14]. Pellegrino and associates
found that all members of a group of long-term pediatric
survivors with maternally transmitted HIV infection had
elevated total serum IgE levels and made anti-HIV-1 IgE
capable of inhibiting HIV replication in vitro; the inhibi-
tory effect was reversed when IgE was removed using
immunoaffinity columns or anti-IgE antibody[15].
In a study involving 700 asymptomatic subjects from
Tanzania, Bereczky and associates found that high IgE
(but not IgG) anti-P. falciparum antibody was associated
with a reduced risk for subsequent development of
clinically evident malaria [16]. Duarte et al also found
that P. falciparum-specific IgE responses contributed to
the control of malaria, particularly in asymptomatic
individuals [17]. There are also reports that IgE antibody
can provide immunity against B. burgdorferi infection in
children that lasts throughout adulthood [18], and con-
tribute to the expulsion of intestinal parasites such as
N. americanus [19]. The authors have found that IgE
deficiency predisposes to sinopulmonary infection with
common respiratory pathogens, including Streptococcus
pneumoniae, Haemophilus influenzae,a n dMoraxella
catarrhalis in patients of their allergy-immunology clinic
[22].
Protection against autoimmune disease
The prevalence of autoimmune disease is recognized to
be increased in persons with immunoglobulin deficien-
cies - particularly those with IgA hypogammaglobuline-
mia [23]. The authors have documented a similar
predisposition in AIC patients with deficiencies in IgE
[22]. There are potentially a number of mechanisms
that could explain this association (Figure 6).
Figure 6 Potential consequences of IgE hypogammaglobulinemia.
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Hence, as is postulated with IgA, it is possible that IgE
protects against autoimmunization by preventing the
systemic absorption of mucosal antigens [23]. A lack of
antigen exclusion at the mucosal barrier could allow
exogenous antigens to induce autoimmune responses by
stimulating autoreactive lymphocytes through molecular
mimicry [24,25]; by promoting immune complex forma-
tion [26]; by super-antigen-induced polyclonal activation
of lymphocytes [27]; by inducing a perturbation of the
idiotypic network [28]; and/or by aberrant induction of
MHC class II antigens [29].
Evidence also indicates that rather than merely prim-
ing mast cells to respond to specific antigen, IgE, in the
absence of cross-linking agents, favorably influences
mast cell survival, receptor expression, and mediator
release, and hence, has an important and active role in
facilitating immune responses [30]. Mast cells have been
shown to be essential intermediaries in Treg induced
allograft tolerance in mice [31]; it is possible, therefore,
that IgE deficiency predisposes to autoimmunity by
adversely effecting mast cell survival and function. It is
also possible that common genetic factors predispose an
individual to both IgE deficiency and autoimmune dis-
ease, or that low levels of IgE merely reflect an imbal-
ance between Th1 and Th2 lymphocyte activity. That, in
turn, favors the development of Th1-mediated autoim-
mune diseases such as systemic lupus erythematosus
and rheumatoid arthritis [32,33]. Systemic lupus erythe-
matosus also may be related to Treg dysregulation,
auto-antibody or anti-apoptotic defect.
Protection against reactive airway disease
The authors found that the prevalence of non-allergic
reactive airway disease (rhinosinusitis, bronchitis and
asthma) was increased in AIC patients with IgE defi-
ciency. However, it was unclear as to whether these
findings were the result of IgE deficiency or reflected
selection bias inherent in allergy practices. In a study
involving 664 pregnant women, Levin and associates
f o u n dt h a tt h e2 1i n d i v i d u a l sw i t hl o ws e r u mI g E( < 2 . 0
IU/mL) had a higher prevalence of symptoms of rhinosi-
nusitis, but a lower prevalence of physician diagnosed
rhinosinusitis when compared to those with normal to
elevated IgE levels [33]. Other studies on the prevalence
of airway disease in IgE deficient patients are likewise
inconclusive [10,12,34]. Experimental evidence is emer-
ging that may provide an explanation for the occurrence
of non-infectious, non-allergic airway inflammation in
some IgE deficient patients. Kang and associates have
demonstrated the occurrence of airway inflammation in
lymphotoxin-deficient a (LTa-/-) mice, accompanied by
diminished levels of IgE and reduced airway responsive-
ness, to both environmental and induced antigen
challenge [35]. The lung inflammation in the LTa-/-
mice is Th1-mediated and alleviated by reconstitution
with IgE. Depletion of IgE in wild-type mice duplicates
the lung pathologies of the LTa-/- mice, which is also
reversed by the administration of IgE. The authors of
this article suggest that the presence of low levels of IgE
impairs the ability of mast cells to respond normally to
airway antigens and, consequently, to produce cytokines
that favor Th2 development (IL-4, IL-13); Th1 responses
to the uncleared antigens then predominate.
Clinical Features
In our experience, the majority of IgE deficient patients
seek medical advice because of persistent sinorespiratory
symptoms that are often assumed to be allergic in origin
[22]. In our own Allergy Immunology clinic population,
79 IgE deficient patients have been identified. All of
these patients tested negative on skin testing or in vitro
allergy testing to a wide spectrum of indoor and outdoor
allergens. When compared to a sex and aged-matched
control group from the same clinic with normal levels
of IgE, these subjects were more likely to complain of
arthralgias, chronic fatigue, and symptoms suggestive of
airway infection. In addition, they had a significantly
higher prevalence of autoimmune disease and, as pre-
viously noted, non-allergic reactive airway disease. Sixty-
two percent of the IgE deficient patients had depressed
levels of other immunoglobulins, most commonly IgG4;
38 percent had selective IgE deficiencies. Not unexpect-
edly, serious infection involving both the upper and
lower respiratory tract was more common in patients
with low IgE and concomitant deficiencies in other
immunoglobulins. Thus, in our experience, patients with
IgE deficiency have a higher prevalence of sinopulmon-
ary disease, chronic fatigue, arthralgias, autoimmune dis-
ease, and concomitant immunoglobulin deficiencies.
At the present time, attempts to replace IgE in persons
with IgE hypogammaglobulinemia are neither feasible
nor recommended. Rather, IgE deficient patients should
be given standard therapy for their underlying conditions.
Immune Dysregulation Associated with High IGE
Levels
Atopic Disease
Elevated levels of IgE may be seen in atopic disease,
with the caveat that normal levels of IgE do not exclude
atopy. Very high levels of IgE may be found in patients
with food allergy, allergic fungal disease (such as sino-
bronchial airway mycoses or allergic fungal sinusitis)
and atopic eczema. Table 3 lists conditions associated
with elevated IgE levels, while Table 4 lists conditions
with very high IgE levels and approaches to their
evaluation.
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Several immune deficiency disorders are associated with
allergic manifestations. These include selective IgA defi-
ciency and Common Variable Immunodeficiency. In
addition, several primary immune deficiency disorders
may demonstrate very high IgE levels[36]. These include
Hyper-IgE syndromes (HIES), Immunodysregulation,
polyendocrinopathy, enteropathy, X-linked syndrome
(IPEX), The Wiskott-Aldrich Syndrome (WAS), Omenn
syndrome and some forms of DiGeorge syndrome.
Hyper-IgE syndrome [37-40] is characterized by highly
elevated IgE levels, skin disease and repeated infections.
IgE levels tend to exceed 10,000 U/mL, although a huge
variability in levels may be observed. HIES syndrome
can be idiopathic, autosomal dominant (AD) or autoso-
mal recessive (AR). Most cases appear to have a
sporadic basis, but mutations in the STAT3 gene is a
feature of the autosomal dominant disorder (also
referred to as type 1). AD HIES is characterized by typi-
c a ls k e l e t a lc h a n g e ss u c ha s“coarse facies”,a b n o r m a l
dentition and infection (Staphylococcal pneumonia and/
or a pneumatocele). In AR HIES (also known as type 2),
recurrent pneumonias, severe viral infections (Mollus-
cum, Herpes simplex), neurological disease and vasculi-
tis may be presenting features and mutations in the
TYK2 gene may be seen.
IPEX i sar a r es y n d r o m em e d i a t e db yar e d u c e do r
absent Treg population [36,41]. The syndrome manifests
as early-onset enteritis (diarrhea), endocrinopathy (type
1 diabetes or hypothyroidism), elevated IgE levels and
dermatitis/eczema. Hematological dyscrazias such as
anemia, thrombocytopenia and eosinophilia are also
observed. IPEX is secondary to mutations of the FOXP3
gene and a resultant deficiency of Treg cells. An
increased Th2 response and elevated IgE levels are
observed.
Wiskott-Aldrich syndrome is an X-linked disorder
characterized by current infection, thrombocytopenia
(with small platelets), neutropenia, eczema, high IgE
levels, a very high prevalence of autoimmunity
Table 3 Elevated IgE: Etiologies and Evaluation
Main category Sub-Category Examples Diagnosis
Atopy Respiratory Rhinitis, asthma, SAM ST/RAST, PFT, Chest CT scan
Food allergy Peanut/shrimp allergy Food ST/RAST, Challenge
Dermatological Eczema, urticaria RAST/Patch, biopsy, culture
Other Allergic Fungal Sinusitis ST/RAST/Sinus imaging
Immune Deficiency Mixed T and B Omenn syndrome Flow, Immune tests
Syndromic DiGeorge, WAS, HIES Genetic, platelet, clinical
Dysregulation IPEX Treg cell studies
Humoral Selective IgA deficiency IgA level, functional antibody
Infection Bacterial Pertussis, S. Aureus Cultures, serology, clinical
Fungal Aspergillus, Candida Cultures, biopsy, serology
Viral EBV, CMV, HIV Serology, PCR, cultures
Mycobacteria Leprosy, TB Clinical, biopsy, culture
Parasitic infestation Helminth Strongyloid, others Clinical, serology, stool exam
Protozoan Malaria Clinical, blood smear
Malignancy Hematological Myeloma, Lymphoma SPEP***, Bone marrow
Solid tumor Lung/colon/Breast Radiology, biopsy
Inflammatory Vasculitides Kawasaki, PAN*, CSS** ANCA, biopsy
Inflammatory Arthritis Rheumatoid arthritis Rheumatoid factor, CCP****
Dermatological Blistering disease Bullous pemphigoid Biopsy, antibody
Idiopathic Alopecia areata Clinical, biopsy
Systemic disease Renal Nephrotic syndrome Urine protein, biopsy
Intoxication Medications, alcohol History, toxicology
Pulmonary Cystic fibrosis CFTR Mutation, sweat chloride
Others Miscellaneous RA, burns, Nicotine Serology, history etc
* PAN- Polyarteritis nodasa, **CSS- Churg-Strauss Syndrome, ***SPEP- serum protein electrophoresis,
****CCP- cyclic citrullinated peptide
Table 4 Conditions with very high IgE levels
Extreme IgE Elevation
Allergic fungal disease Lympho-reticular Malignancy
HIV infection Parasitic Disease
Atopic Dermatitis and Food Allergy Netherton Syndrome
Hyper-IgE syndrome IgE Myeloma
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bowel disease) and malignancy. The defect lies in the
WAS protein (or WASP) that is crucial to T cell, plate-
let and neutrophil function.
Omenn syndrome is a rare disorder presenting with
recurrent infection, diarrhea, alopecia, eczema/erythro-
derma, lymphadenopathy, hepatosplenomegaly, eosino-
philia and elevated IgE levels. Immune assessment
shows elevated IgE levels in spite of deficiency in B cells
numbers, panhypogammaglobulinemia, oligoclonal, non-
functional T cell expansion and excessive Th2 skewing.
The patients demonstrate one of several defects: muta-
tions in RAG genes, Artemis gene, IL-7 receptor encod-
i n gg e n ea n dt h eR M R Pg e n e( R N Ac o m p o n e n to f
mitochondrial RNA-processing endoribonuclease).
A subgroup of patients with DiGeorge syndrome may
present not only with the profound T cell defect, seen
with thymic aplasia, but also with findings consistent
with Omenn syndrome (including elevated IgE levels
and eosinophilia).
Systemic Infections
Elevated IgE levels have been described in a variety of
bacterial, fungal, mycobacterial and viral infections (listed
in Table 4). Leprosy [42] and tuberculosis [43] have
rarely been associated with elevated IgE levels [44,45].
Elevated IgE levels have also been described in viral infec-
tions (Epstein-Barr Virus and Cytomegalovirus). HIV
infection is a well-recognized cause for elevated IgE
levels [46-48]. Elevated IgE levels have been described in
both adults and in children infected with HIV-1 [49], and
are associated with a poorer prognosis [50]. A hyper-IgE-
like syndrome and severe eczema have also been
described with advanced HIV-1 infection [51].
Parasitic Disease
Ascaris [52], Capillariasis [53], Paragonimiasis [54], Fas-
ciola hepatica [55,56], Schistosomiasis [57,58], Hook-
worm (Trichuriasis) [59], Echinococcus [60],
Onchocercariasis [61] and Malaria [62] have all been
associated with elevated IgE levels. Of the many parasi-
tic disorders, only a few are directly relevant to North
American and these will be reviewed below. Giardiasis,
Strongyloidiasis, Trichinella spiralis and Toxocara spe-
cies occur with some frequency and have certain distinct
and unique presentations.
Strongyloidiasis and its systemic consequences were
reviewed by the authors recently [63]. Infection with
S. stercoralis occurs when the skin of the feet contact
free-living filariform larvae in the soil. The filariform lar-
vae penetrate the skin and invade the blood vessels and
subsequently enter the alveoli of the lung, where they
are coughed up, swallowed and undergo maturation in
the duodenum and jejunum. Over half the patients who
harbor S. stercoralis have symptoms are related to the
GI tract invasion, lung invasion or dissemination with
strongyloid hyperinfection. The latter, usually seen in
patients treated with glucocorticoids or immunosuppres-
sive agents, can be fatal with complications such as sep-
sis, gram negative meningitis and/or respiratory distress
[64,65]. Treatment with ivermectin (200 μg/Kg/day) is
associated with a 90% cure rate.
Toxocariasis is a well recognized zoonotic disease
mediated by the nematode belonging to the genus Tox-
ocara. Adult worms are present in the intestinal tracts
of dogs (T. canis) or cats (T. cati) and human infection
is caused by egg ingestion [66,67]. Infective larvae
migrate through the liver and lung and result in a
plethora of allergic and inflammatory manifestations,
referred to as visceral, ocular or cutaneous larva
migrans. Eosinophilia, elevated IgE and involvement of
brain, muscle, liver and lungs are responsible for the
clinical manifestations. Treatment with albendazole or
mebendazole and diethylcarbamazine may be attempted.
Trichinellosis is mediated by the nematode, Trichi-
nella spiralis, transmitted by eating undercooked pork or
larval forms present in cyst form in striated muscle [68].
Many patients may remain asymptomatic, while some
patients develop abdominal pain, diarrhea, fever and
excruciating myalgia (calf or masseter muscle). During
the invasive stage of the illness, allergic phenomena such
as urticaria or periorbital angioedema may occur. The
disease is treated with albendazole and some studies have
suggested a beneficial effect for glucocorticoids during
the allergic and inflammatory stages of the disease.
Giardia lamblia is a protozoan parasite that infects
humans following the ingestion of infectious cysts
(fecal-oral route or from contaminated food or well
water). Symptoms include abdominal cramps, bloating,
watery diarrhea and malabsorption. Elevated IgE levels
and eosinophilia have been described [69]. Treatment
with metronidazole, tinidazole, nitazoxanide or paramo-
mycin may be variably effective, with paramomycin
reserved for infected pregnant women.
Neoplasia
A variety of neoplastic and hematological disorders have
been associated with IgE.
Solid tumors such as cancers of the lung, colon, pros-
tate and breast have been reported to elevate IgE levels
[70]. These may be the result of dysregulation of the
Th1/Th2-IgE axis [71]. Other neoplastic conditions
known to present with elevated IgE levels include IgE
myeloma and malignant lymphoma. Eosinophilia and
elevated IL-4 and IgE levels have been shown in both
Hodgkin’s disease (serum IgE as well as intracellular IgE
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kin’s lymphoma [72]. In multiple myeloma, polyclonal
elevation of IgE is associated with improved survival [73].
IgE myeloma was first described in 1967 as an “atypi-
cal myeloma immunoglobulin” and since then several
other cases of this rare myeloma have been reported
[74]. The presentation of IgE myeloma is similar to that
of an IgG myeloma, and most patients are diagnosed
between the 6
th and 7
th decades of life.
Inflammatory Disorders
Many other inflammatory disorders have been asso-
ciated with elevated IgE levels. These include Kawasaki
syndrome [75], vasculitides such as polyarteritis nodosa
or Churg-Strauss syndrome[76], Guillian-Barre syn-
drome [77,78], inflammatory neuropathies [79], burns
[80,81], Sjogren’s syndrome [82], certain patients with
rheumatoid arthritis who may also develop IgE rheuma-
toid factors [83], graft-versus-host disease and bone
marrow transplantation [84] and scleroderma-like syn-
dromes [85]. The prognostic or diagnostic role for IgE
in these disorders is unknown
Dermatological Disorders
Several dermatological and inflammatory disorders have
been associated with IgE dysregulation and elevated IgE
levels. Alopecia areata [86,87], erythema nodosum (espe-
cially due to streptococcus)[88], acral dermatitides and
blistering diseases, such as pemphigus, have been asso-
ciated with IgE elevation [89,90].
Systemic and Toxic Disorders
Alcohol ingestion has been associated with elevated IgE
levels [91]. Certain forms of nephritides demonstrate
IgE elevation [92]. The elevation of IgE in these disor-
ders may be due to dysregulation of the IL-4-IL-13 axis.
In idiopathic nephritic syndrome, IL-13 levels are
elevated, while in minimal change disease, polymorph-
isms of the IL-4 gene have been described [93]. Other
conditions reported to show elevated IgE levels include
cystic fibrosis [94] (with associated ABPA-like disease,
probably secondary to increased airway penetration by
allergen), nicotine abuse [95] and pulmonary hemosi-
derosis (Heiner’s syndrome)[96].
Conclusion
Major advancements have been made in our under-
standing of the molecular basis of IgE class switching
including roles for T cells, cytokines and T regulatory
cells in this process. Dysregulation of this process may
result in either elevated IgE levels or IgE deficiency.
Evaluation of a patient with elevated IgE must involve a
detailed differential diagnosis and consideration of var-
ious immunological and non-immunological disorders.
The use of appropriate tests will allow the correct diag-
nosis to be made. This can often assist in the develop-
ment of tailored treatments.
Author details
1Division of Allergy and Immunology, Quillen College of Medicine, East
Tennessee State University, Johnson City, TN 37614, USA.
2Department of
Medicine, Quillen College of Medicine, East Tennessee State University,
Johnson City, TN 37614, USA.
3James H. Quillen VA Medical Center,
Mountain Home, TN, USA.
Authors’ contributions
MP carried out some literature search, partially drafted the manuscript, and
proofread the final version. JKS helped to draft the IgE deficiency aspect of
the manuscript. DSC helped to draft the manuscript, revised it for important
intellectual content, and assisted the finalizing of the manuscript. GK
conceived and managed the study, drafted the manuscript, managed
references, generated figures and tables, and has given final approval of the
version to be published. All authors have read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 21 December 2009
Accepted: 23 February 2010 Published: 23 February 2010
References
1. Williams AF, Barclay AN: The immunoglobulin superfamily–domains for
cell surface recognition. Annu Rev Immunol 1988, 6:381-405.
2. Krishnaswamy G, Hall K, Youngberg G, Hossler F, Johnson D, Block WA,
Huang SK, Kelley J, Chi DS: Regulation of eosinophil-active cytokine
production from human cord blood-derived mast cells. J Interferon
Cytokine Res 2002, 22:379-388.
3. Chi DS, Fitzgerald SM, Krishnaswamy G: Mast cell histamine and cytokine
assays. Methods Mol Biol 2006, 315:203-215.
4. Krishnaswamy G, Ajitawi O, Chi DS: The human mast cell: an overview.
Methods Mol Biol 2006, 315:13-34.
5. Lee SA, Fitzgerald SM, Huang SK, Li C, Chi DS, Milhorn DM,
Krishnaswamy G: Molecular regulation of interleukin-13 and monocyte
chemoattractant protein-1 expression in human mast cells by
interleukin-1beta. Am J Respir Cell Mol Biol 2004, 31:283-291.
6. Shakoory B, Fitzgerald SM, Lee SA, Chi DS, Krishnaswamy G: The role of
human mast cell-derived cytokines in eosinophil biology. J Interferon
Cytokine Res 2004, 24:271-281.
7. Geha RS, Jabara HH, Brodeur SR: The regulation of immunoglobulin E
class-switch recombination. Nat Rev Immunol 2003, 3:721-732.
8. de Vries JE, Punnonen J, Cocks BG, de Waal MR, Aversa G: Regulation of
the human IgE response by IL4 and IL13. Res Immunol 1993, 144:597-601.
9. Marsh DG, Neely JD, Breazeale DR, Ghosh B, Freidhoff LR, Ehrlich-Kautzky E,
Schou C, Krishnaswamy G, Beaty TH: Linkage analysis of IL4 and other
chromosome 5q31.1 markers and total serum immunoglobulin E
concentrations. Science 1994, 264:1152-1156.
10. Polmar SH, Waldmann TA, Balestra ST, Jost MC, Terry WD: Immunoglobulin
E in immunologic deficiency diseases. I. Relation of IgE and IgA to
respiratory tract disease in isolated IgE deficiency, IgA deficiency, and
ataxia telangiectasia. J Clin Invest 1972, 51:326-330.
11. Waldmann TA, Polmar SH, Balestra ST, Jost MC, Bruce RM, Terry WD:
Immunoglobulin E in immunologic deficiency diseases. II. Serum IgE
concentration of patients with acquired hypogammaglobulinemia,
thymoma and hypogammaglobulinemia, myotonic dystrophy, intestinal
lymphangiectasia and Wiskott-Aldrich syndrome. J Immunol 1972,
109:304-310.
12. Ammann AJ, Roth J, Hong R: Recurrent sinopulmonary infections, mental
retardation, and combined IgA and IgE deficiency. J Pediatr 1970,
77:802-804.
13. Schoettler JJ, Schleissner LA, Heiner DC: Familial IgE deficiency associated
with sinopulmonary disease. Chest 1989, 96:516-521.
Pate et al. Clinical and Molecular Allergy 2010, 8:3
http://www.clinicalmolecularallergy.com/content/8/1/3
Page 11 of 1314. Secord EA, Kleiner GI, Auci DL, Smith-Norowitz T, Chice S, Finkielstein A,
Nowakowski M, Fikrig S, Durkin HG: IgE against HIV proteins in clinically
healthy children with HIV disease. J Allergy Clin Immunol 1996, 98:979-984.
15. Pellegrino MG, Bluth MH, Smith-Norowitz T, Fikrig S, Volsky DJ, Moallem H,
Auci DL, Nowakowski M, Durkin HG: HIV type 1-specific IgE in serum of
long-term surviving children inhibits HIV type 1 production in vitro. AIDS
Res Hum Retroviruses 2002, 18:363-372.
16. Bereczky S, Montgomery SM, Troye-Blomberg M, Rooth I, Shaw MA,
Farnert A: Elevated anti-malarial IgE in asymptomatic individuals is
associated with reduced risk for subsequent clinical malaria. Int J
Parasitol 2004, 34:935-942.
17. Duarte J, Deshpande P, Guiyedi V, Mecheri S, Fesel C, Cazenave PA,
Mishra GC, Kombila M, Pied S: Total and functional parasite specific IgE
responses in Plasmodium falciparum-infected patients exhibiting
different clinical status. Malar J 2007, 6:1.
18. Bluth MH, Robin J, Ruditsky M, Norowitz KB, Chice S, Pytlak E,
Nowakowski M, Durkin HG, Smith-Norowitz TA: IgE anti-Borrelia
burgdorferi components (p18, p31, p34, p41, p45, p60) and increased
blood CD8+CD60+ T cells in children with Lyme disease. Scand J
Immunol 2007, 65:376-382.
19. Pritchard DI, Walsh EA: The specificity of the human IgE response to
Necator americanus. Parasite Immunol 1995, 17:605-607.
20. Reali E, Greiner JW, Corti A, Gould HJ, Bottazzoli F, Paganelli G, Schlom J,
Siccardi AG: IgEs targeted on tumor cells: therapeutic activity and
potential in the design of tumor vaccines. Cancer Res 2001, 61:5517-5522.
21. Fu SL, Pierre J, Smith-Norowitz TA, Hagler M, Bowne W, Pincus MR,
Mueller CM, Zenilman ME, Bluth MH: Immunoglobulin E antibodies from
pancreatic cancer patients mediate antibody-dependent cell-mediated
cytotoxicity against pancreatic cancer cells. Clin Exp Immunol 2008,
153:401-409.
22. Smith JK, Krishnaswamy GH, Dykes R, Reynolds S, Berk SL: Clinical
manifestations of IgE hypogammaglobulinemia. Ann Allergy Asthma
Immunol 1997, 78:313-318.
23. Liblau RS, Bach JF: Selective IgA deficiency and autoimmunity. Int Arch
Allergy Immunol 1992, 99:16-27.
24. Oldstone MB: Molecular mimicry and immune-mediated diseases. FASEB J
1998, 12:1255-1265.
25. Oldstone MB: Molecular mimicry, microbial infection, and autoimmune
disease: evolution of the concept. Curr Top Microbiol Immunol 2005,
296:1-17.
26. Cunningham-Rundles C, Brandeis WE, Pudifin DJ, Day NK, Good RA:
Autoimmunity in selective IgA deficiency: relationship to anti-bovine
protein antibodies, circulating immune complexes and clinical disease.
Clin Exp Immunol 1981, 45:299-304.
27. Paliard X, West SG, Lafferty JA, Clements JR, Kappler JW, Marrack P,
Kotzin BL: Evidence for the effects of a superantigen in rheumatoid
arthritis. Science 1991, 253:325-329.
28. Cooke A, Lydyard PM, Roitt IM: Autoimmunity and idiotypes. Lancet 1984,
2:723-725.
29. Sarvetnick N, Liggitt D, Pitts SL, Hansen SE, Stewart TA: Insulin-dependent
diabetes mellitus induced in transgenic mice by ectopic expression of
class II MHC and interferon-gamma. Cell 1988, 52:773-782.
30. Kitaura J, Song J, Tsai M, Asai K, Maeda-Yamamoto M, Mocsai A,
Kawakami Y, Liu FT, Lowell CA, Barisas BG, Galli SJ, Kawakami T: Evidence
that IgE molecules mediate a spectrum of effects on mast cell survival
and activation via aggregation of the FcepsilonRI. Proc Natl Acad Sci USA
2003, 100:12911-12916.
31. Lu LF, Lind EF, Gondek DC, Bennett KA, Gleeson MW, Pino-Lagos K,
Scott ZA, Coyle AJ, Reed JL, Van SJ, Strom TB, Zheng XX, Noelle RJ: Mast
cells are essential intermediaries in regulatory T-cell tolerance. Nature
2006, 442:997-1002.
32. Chan RW, Lai FM, Li EK, Tam LS, Chow KM, Li PK, Szeto CC: Imbalance of
Th1/Th2 transcription factors in patients with lupus nephritis.
Rheumatology (Oxford) 2006, 45:951-957.
33. Canete JD, Martinez SE, Farres J, Sanmarti R, Blay M, Gomez A, Salvador G,
Munoz-Gomez J: Differential Th1/Th2 cytokine patterns in chronic
arthritis: interferon gamma is highly expressed in synovium of
rheumatoid arthritis compared with seronegative spondyloarthropathies.
Ann Rheum Dis 2000, 59:263-268.
34. Levy DA, Chen J: Healthy IgE-deficient person. N Engl J Med 1970,
283:541-542.
35. Kang HS, Blink SE, Chin RK, Lee Y, Kim O, Weinstock J, Waldschmidt T,
Conrad D, Chen B, Solway J, Sperling AI, Fu YX: Lymphotoxin is required
for maintaining physiological levels of serum IgE that minimizes Th1-
mediated airway inflammation. J Exp Med 2003, 198:1643-1652.
36. Ozcan E, Notarangelo LD, Geha RS: Primary immune deficiencies with
aberrant IgE production. J Allergy Clin Immunol 2008, 122:1054-1062.
37. Ring J, Landthaler M: Hyper-IgE syndromes. Curr Probl Dermatol 1989,
18:79-88.
38. Heimall J, Freeman A, Holland SM: Pathogenesis of Hyper IgE Syndrome.
Clin Rev Allergy Immunol 2009.
39. Tangye SG, Cook MC, Fulcher DA: Insights into the role of STAT3 in
human lymphocyte differentiation as revealed by the hyper-IgE
syndrome. J Immunol 2009, 182:21-28.
40. Minegishi Y, Karasuyama H: Genetic origins of hyper-IgE syndrome. Curr
Allergy Asthma Rep 2008, 8:386-391.
41. Gambineri E, Perroni L, Passerini L, Bianchi L, Doglioni C, Meschi F,
Bonfanti R, Sznajer Y, Tommasini A, Lawitschka A, Junker A, Dunstheimer D,
Heidemann PH, Cazzola G, Cipolli M, Friedrich W, Janic D, Azzi N,
Richmond E, Vignola S, Barabino A, Chiumello G, Azzari C, Roncarolo MG,
Bacchetta R: Clinical and molecular profile of a new series of patients
with immune dysregulation, polyendocrinopathy, enteropathy, X-linked
syndrome: inconsistent correlation between forkhead box protein 3
expression and disease severity. J Allergy Clin Immunol 2008,
122:1105-1112.
42. Smith DL, Bahna SL, Gillis TP, Clements BH: Atopy and IgE in patients with
leprosy. J Allergy Clin Immunol 1990, 85:795-800.
43. Imai T, Katada H, Mikami R, Nishikawa K, Sawaki M, Ishibashi J, Konoike Y,
Sawaki M, Nakano H, Mikasa K: [Serum IgE level in pulmonary
tuberculosis. Comparison with other respiratory diseases]. Kekkaku 1984,
59:483-490.
44. Ellertsen LK, Wiker HG, Egeberg NT, Hetland G: Allergic sensitisation in
tuberculosis and leprosy patients. Int Arch Allergy Immunol 2005,
138:217-224.
45. Yong AJ, Grange JM, Tee RD, Beck JS, Bothamley GH, Kemeny DM,
Kardjito T: Total and anti-mycobacterial IgE levels in serum from patients
with tuberculosis and leprosy. Tubercle 1989, 70:273-279.
46. Marone G, Florio G, Triggiani M, Petraroli A, de PA: Mechanisms of IgE
elevation in HIV-1 infection. Crit Rev Immunol 2000, 20:477-496.
47. Mazza DS, Grieco MH, Reddy MM, Meriney D: Serum IgE in patients with
human immunodeficiency virus infection. Ann Allergy Asthma Immunol
1995, 74:411-414.
48. Ferrazzi M, De Rinaldis ML, Salotti A, Cirelli A: Serum IgE levels in human
immunodeficiency virus (HIV)-1 infected patients: correlation between
IgE and CD4+ cells. Riv Eur Sci Med Farmacol 1993, 15:67-70.
49. Zar HJ, Latief Z, Hughes J, Hussey G: Serum immunoglobulin E levels in
human immunodeficiency virus-infected children with pneumonia.
Pediatr Allergy Immunol 2002, 13:328-333.
50. Rancinan C, Morlat P, Chene G, Guez S, Baquey A, Beylot J, Salamon R: IgE
serum level: a prognostic marker for AIDS in HIV-infected adults?. J
Allergy Clin Immunol 1998, 102:329-330.
51. Paganelli R, Scala E, Ansotegui IJ, Mezzaroma I, Pinter E, Ferrara R,
D’Offizi GP, Aiuti F: Hyper IgE syndrome induced by HIV infection.
Immunodeficiency 1993, 4:149-152.
52. Fincham JE, Markus MB, van der ML, Adams VJ, van Stuijvenberg ME,
Dhansay MA: Ascaris, co-infection and allergy: the importance of analysis
based on immunological variables rather than egg excretion. Trans R Soc
Trop Med Hyg 2007, 101:680-682.
53. Rosenberg EB, Whalen GE, Bennich H, Johansson SG: Increased circulating
IgE in a new parasitic disease–human intestinal capillariasis. N Engl J Med
1970, 283:1148-1149.
54. Kong Y, Ito A, Yang HJ, Chung YB, Kasuya S, Kobayashi M, Liu YH, Cho SY:
Immunoglobulin G (IgG) subclass and IgE responses in human
paragonimiases caused by three different species. Clin Diagn Lab
Immunol 1998, 5:474-478.
55. Espino AM, Osuna A, Gil R, Hillyer GV: Fasciola hepatica: humoral and
cytokine responses to a member of the saposin-like protein family
following delivery as a DNA vaccine in mice. Exp Parasitol 2005,
110:374-383.
56. Pfister K, Turner K, Currie A, Hall E, Jarrett EE: IgE production in rat
fascioliasis. Parasite Immunol 1983, 5:587-593.
Pate et al. Clinical and Molecular Allergy 2010, 8:3
http://www.clinicalmolecularallergy.com/content/8/1/3
Page 12 of 1357. Jiz M, Friedman JF, Leenstra T, Jarilla B, Pablo A, Langdon G, Pond-Tor S,
Wu HW, Manalo D, Olveda R, Acosta L, Kurtis JD: Immunoglobulin E (IgE)
responses to paramyosin predict resistance to reinfection with
Schistosoma japonicum and are attenuated by IgG4. Infect Immun 2009,
77:2051-2058.
58. Makhlouf LM, Serwah A, bd El-Hamid AD, Hussein EM, Saad RM: INF-
gamma, IL-5 and IgE profiles in chronic schistosomiasis mansoni
Egyptian patients with or without hepatitis C infection. J Egypt Soc
Parasitol 2006, 36:177-196.
59. Loukas A, Prociv P: Immune responses in hookworm infections. Clin
Microbiol Rev 2001, 14:689-703, table..
60. Khabiri AR, Bagheri F, Assmar M, Siavashi MR: Analysis of specific IgE and
IgG subclass antibodies for diagnosis of Echinococcus granulosus.
Parasite Immunol 2006, 28:357-362.
61. Abraham D, Leon O, Schnyder-Candrian S, Wang CC, Galioto AM,
Kerepesi LA, Lee JJ, Lustigman S: Immunoglobulin E and eosinophil-
dependent protective immunity to larval Onchocerca volvulus in mice
immunized with irradiated larvae. Infect Immun 2004, 72:810-817.
62. Duarte J, Deshpande P, Guiyedi V, Mecheri S, Fesel C, Cazenave PA,
Mishra GC, Kombila M, Pied S: Total and functional parasite specific IgE
responses in Plasmodium falciparum-infected patients exhibiting
different clinical status. Malar J 2007, 6:1.
63. Vadlamudi RS, Chi DS, Krishnaswamy G: Intestinal strongyloidiasis and
hyperinfection syndrome. Clin Mol Allergy 2006, 4:8.
64. Olsen A, van LL, Marti H, Polderman T, Polman K, Steinmann P, Stothard R,
Thybo S, Verweij JJ, Magnussen P: Strongyloidiasis - the most neglected
of the neglected tropical diseases?. Trans R Soc Trop Med Hyg 2009.
65. Khasawneh F, Sreedhar R, Chundi V: Strongyloides hyperinfection: an
unusual cause of respiratory failure. Ann Intern Med 2009, 150:570-571.
66. Gawor J, Borecka A, Dobosz S, Marczynska M, Zarnowska-Prymek H,
Trzebicka A, Juszko J: [Toxocariasis in children–difficult clinical problem].
Przegl Epidemiol 2008, 62:407-413.
67. Obwaller A, Jensen-Jarolim E, Auer H, Huber A, Kraft D, Aspock H: Toxocara
infestations in humans: symptomatic course of toxocarosis correlates
significantly with levels of IgE/anti-IgE immune complexes. Parasite
Immunol 1998, 20:311-317.
68. Gottstein B, Pozio E, Nockler K: Epidemiology, diagnosis, treatment, and
control of trichinellosis. Clin Microbiol Rev 2009, 22:127-45, Table..
69. Geller M, Geller M, Flaherty DK, Black P, Madruga M: Serum IgE levels in
giardiasis. Clin Allergy 1978, 8:69-71.
70. Jensen-Jarolim E, Achatz G, Turner MC, Karagiannis S, Legrand F, Capron M,
Penichet ML, Rodriguez JA, Siccardi AG, Vangelista L, Riemer AB, Gould H:
AllergoOncology: the role of IgE-mediated allergy in cancer. Allergy 2008,
63:1255-1266.
71. Lucey DR, Clerici M, Shearer GM: Type 1 and type 2 cytokine
dysregulation in human infectious, neoplastic, and inflammatory
diseases. Clin Microbiol Rev 1996, 9:532-562.
72. Hsu SM: IgE in Reed-Sternberg cells. Blood 1992, 80:286-287.
73. Matta GM, Battaglio S, Dibello C, Napoli P, Baldi C, Ciccone G, Coscia M,
Boccadoro M, Massaia M: Polyclonal immunoglobulin E levels are
correlated with hemoglobin values and overall survival in patients with
multiple myeloma. Clin Cancer Res 2007, 13:5348-5354.
74. Lloyd L, Klingberg SL, Kende M, Howell JF, Clague AE: A case of IgE
multiple myeloma. Pathology 2003, 35:87-89.
75. Kusakawa S, Heiner DC: Elevated levels of immunoglobulin E in the acute
febrile mucocutaneous lymph node syndrome. Pediatr Res 1976,
10:108-111.
76. Krous HF, Clausen CR, Ray CG: Elevated immunoglobulin E in infantile
polyarteritis nodosa. J Pediatr 1974, 84:841-845.
77. Huang JT: Serum IgE concentrations in neurological diseases. Ann Allergy
1975, 34:1-6.
78. Roca GA, Palomeque RA, Pastor D, X, Molinero EC, Jimenez GR: [Guillain-
Barre syndrome: a study of 13 children]. An Esp Pediatr 1993, 39:513-516.
79. Horiuchi I, Kawano Y, Yamasaki K, Matsuo H, Minohara M, Nakamura T,
Hashiguchi H, Ohyagi Y, Yamada T, Kira J: Heightened IgE response to
mite antigens in inflammatory neuropathies. J Neurol Sci 1999, 166:77-80.
80. Polacek V, Jira M, Fara M, Strejcek J, Konigova R: Immunoglobulin E (IgE) in
patients with severe burns. Burns Incl Therm Inj 1987, 13:458-461.
81. Elagina LV, Lagvilava MG, Gordeev VF: [Value of determining serum
immunoglobulin E in burn patients]. Klin Med (Mosk) 1986, 64:124-126.
82. Azuma N, Katada Y, Harada Y, Arimoto H, Kimura Y, Terada H, Tsujino K,
Kida H, Yamamoto S, Kudo E, Umeshita M, Mima T, Saeki Y: [Case of
primary Sjogren’s syndrome with hypereosinophilia and elevation of
serum IgE: measurements of serum IL-4, IL-5 and the IgG subclass].
Arerugi 2005, 54:646-651.
83. Ferreira RA, Ferriani VP, Sopelete MC, Silva DA, Mineo JR, Kiss MH, Silva CH:
Immunoglobulin E-rheumatoid factor in juvenile rheumatoid arthritis.
Rev Hosp Clin Fac Med Sao Paulo 2002, 57:209-216.
84. Heyd J, Donnenberg AD, Burns WH, Saral R, Santos GW: Immunoglobulin E
levels following allogeneic, autologous, and syngeneic bone marrow
transplantation: an indirect association between hyperproduction and
acute graft-v-host disease in allogeneic BMT. Blood 1988, 72:442-446.
85. Romano C, Sellitto A, De FU, Rossiello R, Rossiello L, Giunta R, Lucivero G: A
scleroderma-like cutaneous syndrome associated with a marked Th2-
type immune response occurring after a prosthetic joint implant. J Clin
Rheumatol 2009, 15:133-137.
86. Tokura Y, Sugita K, Kabashima K, Ito T, Yagi H: Alopecia universalis
associated with impaired interleukin-4 production and low serum IgE
level. J Am Acad Dermatol 2007, 57:S22-S25.
87. Kasumagic-Halilovic E, Prohic A: Serum levels of total immunoglobulin e
in patients with alopecia areata: relationship with clinical type of the
disease. Acta Dermatovenerol Croat 2006, 14:149-152.
88. Mandalenaki-Lambrou C, Thomaidis T, Benetos S, Ladis B, Matsaniotis N:
Immunoglobulin E in erythema nodosum. Arch Dis Child 1976, 51:391-393.
89. Bowszyc-Dmochowska M, Dmochowski M: Immediate hypersensitivity
phenomena in bullous pemphigoid: critical concepts. JM e d2002,
33:189-198.
90. Iwata Y, Komura K, Kodera M, Usuda T, Yokoyama Y, Hara T, Muroi E,
Ogawa F, Takenaka M, Sato S: Correlation of IgE autoantibody to BP180
with a severe form of bullous pemphigoid. Arch Dermatol 2008,
144:41-48.
91. Gonzalez-Quintela A, Vidal C, Gude F: Alcohol-induced alterations in
serum immunoglobulin e (IgE) levels in human subjects. Front Biosci
2002, 7:e234-e244.
92. bdel-Hafez M, Shimada M, Lee PY, Johnson RJ, Garin EH: Idiopathic
Nephrotic Syndrome and Atopy: Is There a Common Link?. Am J Kidney
Dis 2009.
93. Cheung W, Wei CL, Seah CC, Jordan SC, Yap HK: Atopy, serum IgE, and
interleukin-13 in steroid-responsive nephrotic syndrome. Pediatr Nephrol
2004, 19:627-632.
94. Latzin P, Hartl D, Regamey N, Frey U, Schoeni MH, Casaulta C: Comparison
of serum markers for allergic bronchopulmonary aspergillosis in cystic
fibrosis. Eur Respir J 2008, 31:36-42.
95. Cozen W, az-Sanchez D, James GW, Zadnick J, Cockburn MG, Gill PS,
Masood R, Hamilton AS, Jyrala M, Mack TM: Th1 and Th2 cytokines and
IgE levels in identical twins with varying levels of cigarette
consumption. J Clin Immunol 2004, 24:617-622.
96. Moissidis I, Chaidaroon D, Vichyanond P, Bahna SL: Milk-induced
pulmonary disease in infants (Heiner syndrome). Pediatr Allergy Immunol
2005, 16:545-552.
doi:10.1186/1476-7961-8-3
Cite this article as: Pate et al.: Regulation and dysregulation of
immunoglobulin E: a molecular and clinical perspective. Clinical and
Molecular Allergy 2010 8:3.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Pate et al. Clinical and Molecular Allergy 2010, 8:3
http://www.clinicalmolecularallergy.com/content/8/1/3
Page 13 of 13